摘要
淋巴瘤是来源于成熟淋巴细胞的恶性肿瘤,B细胞受体(B cell receptor,BCR)信号通路在B细胞的发育和维持中起重要作用。恶性B细胞的生长和存活由BCR及其信号通路介导。目前,已相继研发了针对通路的各种靶酶如Syk、Btk及PI3K的抑制剂。该文对BCR信号通路及其靶向抑制剂在恶性淋巴瘤中作用的研究进展做一综述。
Lymphoma is a malignancy of mature lymphocytes. Signalling through the B cell receptor （BCR） is central to the development and maintenance of B cells. In light of the numerous proliferative and survival pathways activated downstream of the BCR, it comes as no surprise that malignant B cells would co-opt this receptor to promote their own growth and survival. Compounds that inhibit various components of this pathway, including spleen tyrosine kinase （Syk）, Bruton＇ s tyrosine kinase （ Btk）, and phosphoinositol-3 kinase （ PD K）, have been developed. In this paper, the B-ceU receptor signaling and its targeted inhibitors of lymphoid malignancies are reviewed.
出处
《中国药理学通报》
CAS
CSCD
北大核心
2014年第5期604-607,共4页
Chinese Pharmacological Bulletin
基金
国家自然科学基金资助项目(No 81173075,81330081)
高校博士学科点专项科研基金(No 20123420110003)
安徽省青年科学基金资助项目(No 1408085QH173)
